Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | hydroxysteroid 11-beta dehydrogenase 1 | Starlite/ChEMBL | References |
Homo sapiens | hydroxysteroid (11-beta) dehydrogenase 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium ulcerans | short chain dehydrogenase | Get druggable targets OG5_132866 | All targets in OG5_132866 |
Mycobacterium tuberculosis | Probable oxidoreductase | Get druggable targets OG5_132866 | All targets in OG5_132866 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxysteroid (11-beta) dehydrogenase 1 | 292 aa | 250 aa | 24.8 % |
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxysteroid 11-beta dehydrogenase 1 | 292 aa | 246 aa | 25.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | sulfite reductase | 0.0218 | 0.0855 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0353 | 0.355 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0353 | 0.355 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0353 | 0.355 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0175 | 0 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0353 | 0.355 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0353 | 0.355 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0353 | 0.355 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0353 | 0.355 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0353 | 0.355 | 1 |
Leishmania major | p450 reductase, putative | 0.0353 | 0.355 | 1 |
Brugia malayi | flavodoxin family protein | 0.0353 | 0.355 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0353 | 0.355 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0353 | 0.355 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0178 | 0.0054 | 0.0151 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0218 | 0.0855 | 0.2407 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0676 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0353 | 0.355 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0353 | 0.355 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0353 | 0.355 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0353 | 0.355 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0353 | 0.355 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0313 | 0.2749 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0353 | 0.355 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0353 | 0.355 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0175 | 0 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0353 | 0.355 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0353 | 0.355 | 1 |
Giardia lamblia | Hypothetical protein | 0.0313 | 0.2749 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0353 | 0.355 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Inhibition of 11betaHSD2 at 100 uM by cell based assay | ChEMBL. | 18578516 | |
IC50 (binding) | = 0.12 uM | Inhibition of human 11betaHSD1 expressed in CHO cells by cell based assay | ChEMBL. | 18578516 |
IC50 (binding) | = 0.12 uM | Inhibition of C57BL/6 mouse 11betaHSD1 in presence of human serum | ChEMBL. | 18578516 |
IC50 (binding) | = 0.23 uM | Inhibition of mouse 11betaHSD1 expressed in CHO cells by cell based assay | ChEMBL. | 18578516 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.